A LONG-TERM EFFECT OF A HUMANIZED ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY IN A PATIENT WITH TAKAYASU ARTERITIS
Vol. 28 No. 1 (2020), Case reports
Vol. 28 No. 1 (2020)

A LONG-TERM EFFECT OF A HUMANIZED ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY IN A PATIENT WITH TAKAYASU ARTERITIS

Case reports
https://doi.org/10.35465/28.1.2020.pp53-59
Published March 13, 2020
Tanya Sapundzhieva
Department of Propedeutic of Internal Diseases, Medical Faculty, Medical University – Plovdiv, Rheumatology Clinic, University Hospital „Kaspela“ – Plovdiv
R. Karalilova
Department of Propedeutic of Internal Diseases, Medical Faculty, Medical University – Plovdiv, Rheumatology Clinic, University Hospital „Kaspela“ – Plovdiv
A. Marinkov
Department of Propedeutic of Internal Diseases, Medical Faculty, Medical University – Plovdiv, Rheumatology Clinic, University Hospital „Kaspela“ – Plovdiv
A. Batalov
Department of Propedeutic of Internal Diseases, Medical Faculty, Medical University – Plovdiv, Rheumatology Clinic, University Hospital „Kaspela“ – Plovdiv
PDF BG/EN

Keywords

Takayasu arteritis, biologic treatment, interleukin-6 (IL-6), tocilizumab

How to Cite

Sapundzhieva, T., Karalilova, R., Marinkov, A., & Batalov, A. (2020). A LONG-TERM EFFECT OF A HUMANIZED ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY IN A PATIENT WITH TAKAYASU ARTERITIS. Rheumatology (Bulgaria), 28(1), 53-59. https://doi.org/10.35465/28.1.2020.pp53-59
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Takayasu arteritis (TAK) is a large-sized vessel vasculitis that involves the aorta and its major branches. The overproduction of interleukin-6 (IL-6) has been proved to play a major role in the pathogenesis of TAK. The following case report describes a 21-year-old woman with refractory TAK, treated with tocilizumab – IL-6 receptor antibody. As a result of the treatment, the clinical manifestations and the abnormal laboratory fi ndings were improved, which allowed the tapering of the glucocorticoids without a consequent relapse of the disease for a follow-up period of 2 years. The results suggest that inhibition of the IL-6 pathway may be a possible treatment option for patients with refractory TAK.
https://doi.org/10.35465/28.1.2020.pp53-59
PDF BG/EN
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.